期刊文献+

维持性血液透析患者血红蛋白波动的临床研究 被引量:2

Clinical research on hemoglobin variability in maintenance hemodialysis patients
原文传递
导出
摘要 目的了解维持性血液透析患者血红蛋白(m)波动情况,初步探讨Hb波动的影响因素。方法选取复旦大学附属中山医院血液透析中心透析龄超过12个月的患者。以Hbll0~120g/L为靶目标值,根据前后两个月的Hb变化值是否达到10gL分为波动组和非波动组。应用多因素Logistic回归分析衄波动的影响因素。结果共163例患者,基线Hb值为(107.52±15.47)g/L,随访期平均lib值为(106.57±15.22)g/L。基线及随访期Hb达标情况大致相似,46.6%-56.4%患者Hb未达标(Hb〈110g/L)。随访期中仅有1.2%患者胁始终达标。患者平均既波动值为8.15±5.01g/L,Hb波动率为27.O%,短期波动在大多数血液透析患者中较常见,少数患者lib长期处于不稳定状态。非波动组患者的透析龄和基础Hb值显著高于波动组(f=-5.032,P=0.048;t=-1.731,P=O.010),促红细胞生成素(EPO)剂量显著低于波动组(t=6.218,P〈0.001)。多因素Logistic回归分析显示,经过透析龄〈24个月、基础Hb〈100g/L等因素校正后,EPO剂量≥200U/(kg·W)与Hb波动显著独立相关(OR=4.7,95%CI3.2-9.3,P=0.030)。结论Hb波动在维持性血液透析患者中普遍存在,少数患者Hb长期处于不稳定状态。Hb波动较大的维持性血液透析患者EPO剂量应用也较大。 Objective To investigate the hemoglobin (Hb) variability in maintenance hemodialysis patients, and analyze the influence factors on Hb fluctuation. Methods Patients undergoing maintenance hemodialysis for over 12 months in Zhongshan Hospital from June 2011 to December 2011 were enrolled. Target value of Hb was 110-120 g/L and hemoglobin fluctuation referred to the fluctuation in Hb ≥ 10 g/L between 2 continuous months. The influence factors on Hb fluctuation were evaluated with multivariate logistic regression analysis. Results In 163 patients enrolled, the baseline Hb value was ( 107.52 ± 15.47) g/L and the 6-month mean Hb was ( 106.57 ± 15.22) g/L. The distributions of Hb were similar before and during the entire follow-up period. Among them, 46.6%-56.4% patients didn't reach the Hb target range (Hb 110-120 g/L). Only 1. 2% patients were always within the target range during the 6 months of follow-up. The average Hb variability was (8.15 ± 5.01 ) g/L and the fluctuation ratio was 27.0%. Short-term fluctuations were common in the majority of hemodialysis patients, but a few patients were with chronic Hb instability. The dialysis age and the basal Hb values of the non-fluctuation group were significantly higher than those of the fluctuation group ( t = - 5. 602, P = 0.048 ; t = - 1. 731, P = 0.010), and the erythropoietin (EPO) dose was significantly lower than that of the fluctuation group (t = 6. 218, P 〈 O. 001 ). Multivariate logistic regression analysis showed that, after adjustment by dialysis age 〈 24 monthsand basic Hb 〈 100 g/L, the EPO dose≥200 U/kg/w) remained significantly and independently associated with the Hb variability in patients with maintenance hemodialysis ( OR = 4. 7, 95% CI 3. 2-9. 3, P = 0. 030). Conclusion Hemoglobin fluctuation is common in patients with maintenance hemodialysis and a few patients are with chronic Hb instability. Patients with substantial Hb fluctuation during maintenance hemodialysis need to use greater doses of EPO.
出处 《中华肾病研究电子杂志》 2015年第3期37-41,共5页 Chinese Journal of Kidney Disease Investigation(Electronic Edition)
基金 上海市卫生局科研课题(20134462) 上海市卫生计生委先进适宜技术推广项目(2013SY048) "十二五"国家科技支撑计划课题(2011BAI10B03) "十二五"农村领域国家科技计划课题(2012BAJ18B00) 卫生部肾脏疾病的防治与血液净化创新产品研发及临床应用评价项目(2011BAI10B03)
关键词 血液透析 血红蛋白波动 促红细胞生成素 Hemodialysis Hemoglobin fluctuation Erythropoietin
  • 相关文献

参考文献13

  • 1KDOQI. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease [ J ]. Am J Kidney Dis, 2006, 47 (5 Suppl 3) : Sll-S145.
  • 2Steven MB, Marshall M J, Rubeen KI, et al. History- adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients [ J l- Clin J Am Soc Nepbrol, 2008, 3(3) : 777-782.
  • 3National Kidney Foundation. K/DIGO clinical practice guidelines for anemia in CKD[J]. Kidney Inter Suppl, 2012, 2(4) : 279-335.
  • 4James PE, David TG, Robert NF, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations [J]. Clin J Am Soc Nephrol, 2006, 1 (6) : 1205- 1210.
  • 5Collins A J, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease &end-stage renal disease in the United States [ J ]. Am J Kidney Dis, 2012, 59(1 ): 401-420.
  • 6Akizawa T, Saito A, Gejyo F, et al. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients [ J ]. Ther Apher Dial, 2014, 18(5): 404-413.
  • 7Cases-Amen6s A, Martinez-Castelao A, Fort-Ros J, et al. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study [J]. Nefrologia, 2014, 34(2): 189-198.
  • 8Deborah LR, Joel DK, Csaha PK, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients [ J]. J Am Soe Nephrol, 2006, 17(4): 1181-1191.
  • 9Wei Y, Rubeen KI, Steven MB, et al. Hemoglobin variability and mortality in ESRD [J]. J Am Soe Nephrol, 2007, 18(12) : 3164- 3170.
  • 10David TG, James PE, Robert NF, et al. Hemoglobin level variability: associations with mortality [ J ]. Clin J Am Soc Nephrol, 2008, 3(1) : 133-138.

同被引文献3

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部